Beyond Air, Inc. (XAIR) Stock Analysis & Investment Frameworks
Beyond Air, Inc. (XAIR) stock analysis on Invetso. Review Beyond Air, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Beyond Air, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Beyond Air, Inc. Key Financial Metrics
- Market Cap: $1.49M
- Revenue: $7.68M
- ROE: -734.86%
- ROIC: -106.06%
- Dividend Yield: N/A
About Beyond Air, Inc.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Beyond Air, Inc. Investment Frameworks
Invetso analyzes Beyond Air, Inc. (XAIR) across the following frameworks:
- Beyond Air, Inc. 10Y Growth Potential
- Beyond Air, Inc. Scenario Analysis
- Beyond Air, Inc. Risks & Opportunities
- Beyond Air, Inc. Economic Moat
- Beyond Air, Inc. Business Model
- Beyond Air, Inc. Management
- Beyond Air, Inc. SWOT Analysis
- Beyond Air, Inc. Porter's 5 Forces
- Beyond Air, Inc. PESTLE Analysis
- Beyond Air, Inc. ESG Analysis